Skip to content
Bomb Report – Lifestyle
Author:
Revolution Medicines, Inc.
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 17, 2026
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
April 15, 2026
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
April 13, 2026
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
April 13, 2026
←
Previous Page
1
2
3